{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T10:09:32Z","timestamp":1789726172143,"version":"4.0.1"},"reference-count":79,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Microbial Pathogenesis"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.micpath.2024.107003","type":"journal-article","created":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T02:08:13Z","timestamp":1728526093000},"page":"107003","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Alcohol consumption as a risk factor for anti-tuberculosis drug induced liver injury: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"196","author":[{"given":"Fan","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuzhen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingyang","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 1","key":"10.1016\/j.micpath.2024.107003_bib2","first-page":"S7","article-title":"Global tuberculosis report 2020 - reflections on the global TB burden, treatment and prevention efforts","volume":"113","author":"Chakaya","year":"2021","journal-title":"Int. J. Infect. Dis. : IJID : official publication of the International Society for Infectious Diseases"},{"issue":"6","key":"10.1016\/j.micpath.2024.107003_bib3","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.03300-2020","article-title":"World Health Organization recommendations on the treatment of drug-resistant tuberculosis, 2020 update","volume":"57","author":"Mirzayev","year":"2021","journal-title":"Eur. Respir. J."},{"issue":"1","key":"10.1016\/j.micpath.2024.107003_bib4","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/crj.13276","article-title":"Drug safety in hospitalized patients with tuberculosis: drug interactions and adverse drug effects","volume":"15","author":"Noor","year":"2021","journal-title":"The clinical respiratory journal"},{"issue":"6","key":"10.1016\/j.micpath.2024.107003_bib5","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1093\/cid\/ciac019","article-title":"Safety of treatment regimens containing bedaquiline and delamanid in the endTB cohort","volume":"75","author":"Hewison","year":"2022","journal-title":"Clin. Infect. Dis. : an official publication of the Infectious Diseases Society of America"},{"issue":"4","key":"10.1016\/j.micpath.2024.107003_bib6","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.jinf.2010.07.009","article-title":"Antituberculosis drug-induced liver injury in chronic hepatitis and cirrhosis","volume":"61","author":"Park","year":"2010","journal-title":"J. Infect."},{"issue":"8","key":"10.1016\/j.micpath.2024.107003_bib7","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02637-17","article-title":"Oxidative stress and first-line antituberculosis drug-induced hepatotoxicity","volume":"62","author":"Yew","year":"2018","journal-title":"Antimicrobial agents and chemotherapy"},{"key":"10.1016\/j.micpath.2024.107003_bib8","article-title":"Urine metabolomics and microbiome analyses reveal the mechanism of anti-tuberculosis drug-induced liver injury, as assessed for causality using the updated RUCAM: a prospective study","volume":"13","author":"Wang","year":"2022","journal-title":"Front. Immunol."},{"issue":"8","key":"10.1016\/j.micpath.2024.107003_bib9","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1053\/j.gastro.2019.02.002","article-title":"Incidence and etiology of drug-induced liver injury in mainland China","volume":"156","author":"Shen","year":"2019","journal-title":"Gastroenterology"},{"issue":"7","key":"10.1016\/j.micpath.2024.107003_bib10","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0021836","article-title":"Incidence, clinical features and impact on anti-tuberculosis treatment of anti-tuberculosis drug induced liver injury (ATLI) in China","volume":"6","author":"Shang","year":"2011","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.micpath.2024.107003_bib11","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1111\/liv.14896","article-title":"Incidence and risk factors of anti-tuberculosis drug induced liver injury (DILI): large cohort study involving 4652 Chinese adult tuberculosis patients","volume":"41","author":"Jiang","year":"2021","journal-title":"Liver Int. : official journal of the International Association for the Study of the Liver"},{"issue":"1","key":"10.1016\/j.micpath.2024.107003_bib12","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1097\/INF.0000000000002192","article-title":"Antituberculosis drug-induced liver injury in children: incidence and risk factors during the two-month intensive phase of therapy","volume":"38","author":"Gafar","year":"2019","journal-title":"Pediatr. Infect. Dis. J."},{"key":"10.1016\/j.micpath.2024.107003_bib13","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/8266878","article-title":"Incidence and temporal trend of antituberculosis drug-induced liver injury: a systematic review and meta-analysis","volume":"2022","author":"Wang","year":"2022","journal-title":"Journal of tropical medicine"},{"issue":"11","key":"10.1016\/j.micpath.2024.107003_bib14","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1086\/598929","article-title":"Safety of fluoroquinolone use in patients with hepatotoxicity induced by anti-tuberculosis regimens","volume":"48","author":"Ho","year":"2009","journal-title":"Clin. Infect. Dis. : an official publication of the Infectious Diseases Society of America"},{"issue":"12","key":"10.1016\/j.micpath.2024.107003_bib15","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0083892","article-title":"Hepatitis C virus co-infection increases the risk of anti-tuberculosis drug-induced hepatotoxicity among patients with pulmonary tuberculosis","volume":"8","author":"Lomtadze","year":"2013","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.micpath.2024.107003_bib16","doi-asserted-by":"crossref","first-page":"640","DOI":"10.7326\/0003-4819-137-8-200210150-00007","article-title":"Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a multicenter clinical trial","volume":"137","author":"Jasmer","year":"2002","journal-title":"Annals of internal medicine"},{"issue":"12","key":"10.1016\/j.micpath.2024.107003_bib17","first-page":"725","article-title":"Risk factors of anti-tuberculosis drugs induced liver injury and its impact on the treatment outcome of patients treated with first line anti-tuberculosis drugs: a historic retrospective cohort study","volume":"33","author":"Sun","year":"2015","journal-title":"Chinese Journal of Infections Diseases"},{"issue":"3","key":"10.1016\/j.micpath.2024.107003_bib18","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.tube.2014.03.006","article-title":"The role of cigarette smoking and liver enzymes polymorphisms in anti-tuberculosis drug-induced hepatotoxicity in Brazilian patients","volume":"94","author":"Zaverucha-do-Valle","year":"2014","journal-title":"Tuberculosis"},{"issue":"1","key":"10.1016\/j.micpath.2024.107003_bib19","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s40264-013-0119-6","article-title":"Anti-tuberculosis drug-induced liver injury in Shanghai: validation of Hy's Law","volume":"37","author":"Shen","year":"2014","journal-title":"Drug Saf."},{"issue":"1","key":"10.1016\/j.micpath.2024.107003_bib20","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ijmyco.2015.10.001","article-title":"Antituberculosis drugs and hepatotoxicity among hospitalized patients in Jos, Nigeria","volume":"5","author":"Isa","year":"2016","journal-title":"International journal of mycobacteriology"},{"issue":"24","key":"10.1016\/j.micpath.2024.107003_bib21","doi-asserted-by":"crossref","first-page":"e982","DOI":"10.1097\/MD.0000000000000982","article-title":"Gender-dimorphic impact of PXR genotype and haplotype on hepatotoxicity during antituberculosis treatment","volume":"94","author":"Wang","year":"2015","journal-title":"Medicine"},{"issue":"3","key":"10.1016\/j.micpath.2024.107003_bib22","doi-asserted-by":"crossref","first-page":"198","DOI":"10.2174\/1574886315666200626164554","article-title":"Evaluation of risk factors for development of anti-tubercular therapy induced hepatotoxicity: a prospective study","volume":"15","author":"Subbalaxmi","year":"2020","journal-title":"Curr. Drug Saf."},{"issue":"19","key":"10.1016\/j.micpath.2024.107003_bib23","first-page":"2920","article-title":"Risk factors for drug-induced liver injuries and its association with SLCO1B1\/ABCB1 gene polymorphisms","volume":"31","author":"Wang","year":"2021","journal-title":"Chinese Journal of Nosocomiology"},{"issue":"5","key":"10.1016\/j.micpath.2024.107003_bib24","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1111\/joim.13129","article-title":"A safe level of alcohol consumption: the right answer demands the right question","volume":"288","author":"Mukamal","year":"2020","journal-title":"Journal of internal medicine"},{"issue":"2","key":"10.1016\/j.micpath.2024.107003_bib25","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1001\/jama.2021.7683","article-title":"Diagnosis and treatment of alcohol-associated liver disease: a review","volume":"326","author":"Singal","year":"2021","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.micpath.2024.107003_bib26","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/nrgastro.2017.116","article-title":"Alcohol, adipose tissue and liver disease: mechanistic links and clinical considerations","volume":"15","author":"Parker","year":"2018","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"1","key":"10.1016\/j.micpath.2024.107003_bib27","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1097\/QAI.0000000000001641","article-title":"Hepatotoxicity during isoniazid preventive therapy and antiretroviral therapy in people living with HIV with severe immunosuppression: a secondary analysis of a multi-country open-label randomized controlled clinical trial","volume":"78","author":"Ngongondo","year":"2018","journal-title":"Journal of acquired immune deficiency syndromes"},{"issue":"8","key":"10.1016\/j.micpath.2024.107003_bib28","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1111\/jcpt.13672","article-title":"The role of the genetic variant FECH rs11660001 in the occurrence of anti-tuberculosis drug-induced liver injury","volume":"47","author":"Zhang","year":"2022","journal-title":"J. Clin. Pharm. Therapeut."},{"issue":"1","key":"10.1016\/j.micpath.2024.107003_bib29","first-page":"64","article-title":"Study on influencing factors of anti-tuberculosis drug-induced liver injury in pulmonary tuberculosis patients complicated with diabetes mellitus","volume":"44","author":"Zhang","year":"2022","journal-title":"Chinese Journal of Antituberculosis"},{"issue":"3","key":"10.1016\/j.micpath.2024.107003_bib30","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0119481","article-title":"Involvement of cytochrome P450 1A1 and glutathione S-transferase P1 polymorphisms and promoter hypermethylation in the progression of anti-tuberculosis drug-induced liver injury: a case-control study","volume":"10","author":"He","year":"2015","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.micpath.2024.107003_bib31","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ijmyco.2015.10.002","article-title":"Incidence of antituberculosis-drug-induced hepatotoxicity and associated risk factors among tuberculosis patients in Dawro Zone, South Ethiopia: a cohort study","volume":"5","author":"Wondwossen","year":"2016","journal-title":"International journal of mycobacteriology"},{"key":"10.1016\/j.micpath.2024.107003_bib32","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jclinepi.2019.12.013","article-title":"No clear choice between Newcastle-Ottawa Scale and Appraisal Tool for Cross-Sectional Studies to assess methodological quality in cross-sectional studies of health-related quality of life and breast cancer","volume":"120","author":"Moskalewicz","year":"2020","journal-title":"Journal of clinical epidemiology"},{"issue":"6","key":"10.1016\/j.micpath.2024.107003_bib33","first-page":"991","article-title":"Isoniazid-related hepatitis: a U.S. Public Health Service cooperative surveillance study","volume":"117","author":"Kopanoff","year":"1978","journal-title":"The American review of respiratory disease"},{"issue":"3","key":"10.1016\/j.micpath.2024.107003_bib34","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/00004836-198109000-00012","article-title":"RISK-FACTORS for isoniazid (INH)-INDUCED liver dysfunction","volume":"3","author":"Dickinson","year":"1981","journal-title":"J. Clin. Gastroenterol."},{"issue":"836","key":"10.1016\/j.micpath.2024.107003_bib35","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1136\/pgmj.71.836.359","article-title":"Antituberculosis treatment-induced hepatotoxicity: role of predictive factors","volume":"71","author":"Singh","year":"1995","journal-title":"Postgrad. Med."},{"issue":"4","key":"10.1016\/j.micpath.2024.107003_bib36","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S0962-8479(96)90098-2","article-title":"Liver injury during antituberculosis treatment: an 11-year study","volume":"77","author":"D\u00f8ssing","year":"1996","journal-title":"Tuber. Lung Dis. : the official journal of the International Union against Tuberculosis and Lung Disease"},{"issue":"2","key":"10.1016\/j.micpath.2024.107003_bib37","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1136\/thx.51.2.132","article-title":"Risk factors for hepatotoxicity from antituberculosis drugs: a case-control study","volume":"51","author":"Pande","year":"1996","journal-title":"Thorax"},{"issue":"11","key":"10.1016\/j.micpath.2024.107003_bib38","first-page":"995","article-title":"Risk factors for hepatotoxicity associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection: experience from three public health tuberculosis clinics","volume":"6","author":"Lee","year":"2002","journal-title":"Int. J. Tubercul. Lung Dis. : the official journal of the International Union against Tuberculosis and Lung Disease"},{"issue":"9","key":"10.1016\/j.micpath.2024.107003_bib39","first-page":"839","article-title":"Lack of toxicity from concomitant directly observed disulfiram and isoniazid-containing therapy for active tuberculosis","volume":"6","author":"Burman","year":"2002","journal-title":"Int. J. Tubercul. Lung Dis. : the official journal of the International Union against Tuberculosis and Lung Disease"},{"issue":"3","key":"10.1016\/j.micpath.2024.107003_bib40","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1086\/345906","article-title":"Isoniazid hepatotoxicity among drug users: the role of hepatitis C","volume":"36","author":"Fern\u00e1ndez-Villar","year":"2003","journal-title":"Clin. Infect. Dis. : an official publication of the Infectious Diseases Society of America"},{"issue":"12","key":"10.1016\/j.micpath.2024.107003_bib41","first-page":"1499","article-title":"The influence of risk factors on the severity of anti-tuberculosis drug-induced hepatotoxicity","volume":"8","author":"Fern\u00e1ndez-Villar","year":"2004","journal-title":"Int. J. Tubercul. Lung Dis. : the official journal of the International Union against Tuberculosis and Lung Disease"},{"issue":"5","key":"10.1016\/j.micpath.2024.107003_bib42","first-page":"534","article-title":"Severe hepatotoxicity due to anti-tuberculosis drugs in Spain","volume":"9","author":"Tost","year":"2005","journal-title":"Int. J. Tubercul. Lung Dis. : the official journal of the International Union against Tuberculosis and Lung Disease"},{"issue":"11","key":"10.1016\/j.micpath.2024.107003_bib43","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1111\/j.1440-1746.2005.04048.x","article-title":"Monitoring and management of antituberculosis drug induced hepatotoxicity","volume":"20","author":"Agal","year":"2005","journal-title":"J. Gastroenterol. Hepatol."},{"issue":"9","key":"10.1016\/j.micpath.2024.107003_bib44","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.2217\/pgs.09.66","article-title":"Genetic variations of NAT2 and CYP2E1 and isoniazid hepatotoxicity in a diverse population","volume":"10","author":"Yamada","year":"2009","journal-title":"Pharmacogenomics"},{"issue":"2","key":"10.1016\/j.micpath.2024.107003_bib45","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1164\/rccm.200911-1783OC","article-title":"Isoniazid-associated hepatitis and antiretroviral drugs during tuberculosis prophylaxis in hiv-infected adults in Botswana","volume":"182","author":"Tedla","year":"2010","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"5","key":"10.1016\/j.micpath.2024.107003_bib46","doi-asserted-by":"crossref","first-page":"596","DOI":"10.5588\/ijtld.11.0591","article-title":"Hepatotoxicity during treatment for multidrug-resistant tuberculosis: occurrence, management and outcome","volume":"16","author":"Keshavjee","year":"2012","journal-title":"Int. J. Tubercul. Lung Dis.: the official journal of the International Union against Tuberculosis and Lung Disease"},{"issue":"6","key":"10.1016\/j.micpath.2024.107003_bib47","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1111\/j.1365-2710.2012.01368.x","article-title":"The roles of GSTM1 and GSTT1 null genotypes and other predictors in anti-tuberculosis drug-induced liver injury","volume":"37","author":"Monteiro","year":"2012","journal-title":"J. Clin. Pharm. Therapeut."},{"issue":"4","key":"10.1016\/j.micpath.2024.107003_bib48","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1590\/S0102-311X2012000400009","article-title":"Hepatotoxicity induced by antituberculosis drugs among patients coinfected with HIV and tuberculosis","volume":"28","author":"Lima Mde","year":"2012","journal-title":"Cad. Sa\u00fade P\u00fablica"},{"issue":"2","key":"10.1016\/j.micpath.2024.107003_bib49","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/jgh.12069","article-title":"Sex, ethnicity, and slow acetylator profile are the major causes of hepatotoxicity induced by antituberculosis drugs","volume":"28","author":"Chamorro","year":"2013","journal-title":"J. Gastroenterol. Hepatol."},{"issue":"2","key":"10.1016\/j.micpath.2024.107003_bib50","doi-asserted-by":"crossref","first-page":"238","DOI":"10.4103\/2249-4863.154661","article-title":"Drug-induced hepatitis and the risk factors for liver injury in pulmonary tuberculosis patients","volume":"4","author":"Gaude","year":"2015","journal-title":"J Family Med Prim Care"},{"issue":"9","key":"10.1016\/j.micpath.2024.107003_bib51","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.5588\/ijtld.14.0829","article-title":"Three months of weekly rifapentine plus isoniazid is less hepatotoxic than nine months of daily isoniazid for LTBI","volume":"19","author":"Bliven-Sizemore","year":"2015","journal-title":"Int. J. Tubercul. Lung Dis. : the official journal of the International Union against Tuberculosis and Lung Disease"},{"issue":"6","key":"10.1016\/j.micpath.2024.107003_bib52","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0157725","article-title":"Hepatotoxicity during treatment for tuberculosis in people living with HIV\/AIDS","volume":"11","author":"Ara\u00fajo-Mariz","year":"2016","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.micpath.2024.107003_bib53","first-page":"219","article-title":"Predictors of hepatotoxicity among patients treated with antituberculous medication","volume":"110","author":"Cusack","year":"2017","journal-title":"Qjm"},{"issue":"1","key":"10.1016\/j.micpath.2024.107003_bib54","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1186\/s12931-019-1256-y","article-title":"The clinical impact of drug-induced hepatotoxicity on anti-tuberculosis therapy: a case control study","volume":"20","author":"Song","year":"2019","journal-title":"Respiratory research"},{"issue":"6","key":"10.1016\/j.micpath.2024.107003_bib55","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.bjid.2019.09.003","article-title":"Relationship of anti-tuberculosis drug-induced liver injury and genetic polymorphisms in CYP2E1 and GST","volume":"23","author":"Santos","year":"2019","journal-title":"Braz. J. Infect. Dis. : an official publication of the Brazilian Society of Infectious Diseases"},{"issue":"7","key":"10.1016\/j.micpath.2024.107003_bib56","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1097\/JCMA.0000000000000119","article-title":"The role of regular liver function monitoring in antituberculosis drug-induced liver injury","volume":"82","author":"Chang","year":"2019","journal-title":"J. Chin. Med. Assoc. : J. Chin. Med. Assoc."},{"key":"10.1016\/j.micpath.2024.107003_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.meegid.2020.104349","article-title":"Association between NR1I2 polymorphisms and susceptibility to anti-tuberculosis drug-induced hepatotoxicity in an Eastern Chinese Han population: a case-control study","volume":"83","author":"Yang","year":"2020","journal-title":"Infect. Genet. Evol. : journal of molecular epidemiology and evolutionary genetics in infectious diseases"},{"issue":"8","key":"10.1016\/j.micpath.2024.107003_bib58","first-page":"699","article-title":"Hepatotoxicity of tuberculosis chemotherapy under general programme conditions in Singapore","volume":"6","author":"Teleman","year":"2002","journal-title":"Int. J. Tubercul. Lung Dis. : the official journal of the International Union against Tuberculosis and Lung Disease"},{"issue":"3","key":"10.1016\/j.micpath.2024.107003_bib59","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/bcpt.13401","article-title":"Combined 5-hydroxymethylcytosine content of human leucocyte antigen-B and human leucocyte antigen-DQB1 as novel biomarker for anti-tuberculosis drug-induced liver injury","volume":"127","author":"Li","year":"2020","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"issue":"10","key":"10.1016\/j.micpath.2024.107003_bib60","article-title":"Incidence and clinical profile of anti-tuberculosis treatment induced hepatitis in a tertiary care hospital in southern India","volume":"14","author":"Juganya","year":"2020","journal-title":"J. Clin. Diagn. Res."},{"key":"10.1016\/j.micpath.2024.107003_bib61","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmpb.2019.105307","article-title":"Comparison of the predictive outcomes for anti-tuberculosis drug-induced hepatotoxicity by different machine learning techniques","volume":"188","author":"Lai","year":"2020","journal-title":"Comput Methods Programs Biomed"},{"key":"10.1016\/j.micpath.2024.107003_bib62","first-page":"223","article-title":"Do genetic polymorphisms of B-cell CLL\/lymphoma 2 confer susceptibility to anti-tuberculous therapy-associated drug-induced liver injury?","volume":"91","author":"Lyu","year":"2020","journal-title":"Int. J. Infect. Dis. : IJID : official publication of the International Society for Infectious Diseases"},{"issue":"4","key":"10.1016\/j.micpath.2024.107003_bib63","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1111\/1348-0421.12877","article-title":"Prospective study of ALDH1A1 gene polymorphisms associated with antituberculosis drug-induced liver injury in western Chinese Han population","volume":"65","author":"Peng","year":"2021","journal-title":"Microbiol. Immunol."},{"issue":"19","key":"10.1016\/j.micpath.2024.107003_bib64","first-page":"2940","article-title":"Association of IL-10 gene polymorphism with susceptibility to pulmonary tuberculosis and liver injury caused by anti-tuberculosis therapy","volume":"31","author":"Ji","year":"2021","journal-title":"Chinese Journal of Nosocomiology"},{"issue":"1","key":"10.1016\/j.micpath.2024.107003_bib65","article-title":"TANC1 methylation as a novel biomarker for the diagnosis of patients with anti-tuberculosis drug-induced liver injury","volume":"11","author":"Wu","year":"2021","journal-title":"Sci. Rep."},{"issue":"30","key":"10.1016\/j.micpath.2024.107003_bib66","first-page":"3837","article-title":"Study on the influencing factors and prognosis of liver injury in patients with newly diagnosed pulmonary tuberculosis and hepatitis B Co-infection during anti-tuberculosis treatment","volume":"24","author":"Li","year":"2021","journal-title":"Chinese General Practice"},{"key":"10.1016\/j.micpath.2024.107003_bib67","doi-asserted-by":"crossref","DOI":"10.1016\/j.meegid.2021.104991","article-title":"Relationship between xanthine oxidase gene polymorphisms and anti-tuberculosis drug-induced liver injury in a Chinese population","volume":"93","author":"Ai","year":"2021","journal-title":"Infect. Genet. Evol. : journal of molecular epidemiology and evolutionary genetics in infectious diseases"},{"key":"10.1016\/j.micpath.2024.107003_bib68","article-title":"Dietary intake of vegetables and cooking oil was associated with drug-induced liver injury during tuberculosis treatment: a preliminary cohort study","volume":"8","author":"Wang","year":"2021","journal-title":"Front. Nutr."},{"key":"10.1016\/j.micpath.2024.107003_bib69","article-title":"Plasma metabolomic and lipidomic alterations associated with anti-tuberculosis drug-induced liver injury","volume":"13","author":"Wang","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"19","key":"10.1016\/j.micpath.2024.107003_bib70","doi-asserted-by":"crossref","DOI":"10.3390\/ijms231911028","article-title":"GSTT1\/GSTM1 genotype and anti-tuberculosis drug-induced hepatotoxicity in Peruvian patients","volume":"23","author":"Jaramillo-Valverde","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.micpath.2024.107003_bib71","doi-asserted-by":"crossref","DOI":"10.3390\/jpm12050790","article-title":"Clinical and genetic risk factors for drug-induced liver injury associated with anti-tuberculosis treatment-A study from patients of Portuguese health centers","volume":"12","author":"Cavaco","year":"2022","journal-title":"J Pers Med"},{"issue":"1","key":"10.1016\/j.micpath.2024.107003_bib72","doi-asserted-by":"crossref","first-page":"324","DOI":"10.15562\/bmj.v11i1.3113","article-title":"Early detection of elevated liver function test in drug-resistant tuberculosis with short term therapy and individual therapy","volume":"11","author":"Azis","year":"2022","journal-title":"Bali Med. J."},{"key":"10.1016\/j.micpath.2024.107003_bib73","doi-asserted-by":"crossref","DOI":"10.1590\/0074-02760210328","article-title":"Homozygotes NAT2\u22175B slow acetylators are highly associated with hepatotoxicity induced by anti-tuberculosis drugs","volume":"117","author":"El-Jaick","year":"2022","journal-title":"Mem. Inst. Oswaldo Cruz"},{"issue":"9","key":"10.1016\/j.micpath.2024.107003_bib74","doi-asserted-by":"crossref","first-page":"e3377","DOI":"10.1093\/cid\/ciaa1255","article-title":"A randomized controlled trial of intravenous N-acetylcysteine in the management of anti-tuberculosis drug-induced liver injury","volume":"73","author":"Moosa","year":"2021","journal-title":"Clin. Infect. Dis. : an official publication of the Infectious Diseases Society of America"},{"issue":"2","key":"10.1016\/j.micpath.2024.107003_bib75","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.tube.2014.10.006","article-title":"Hepatotoxicity from antituberculous therapy in the elderly: a systematic review","volume":"95","author":"Hosford","year":"2015","journal-title":"Tuberculosis"},{"issue":"1","key":"10.1016\/j.micpath.2024.107003_bib76","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S2095-4964(17)60319-4","article-title":"Clinical and experimental research in antituberculosis drug-induced hepatotoxicity: a review","volume":"15","author":"Baskaran","year":"2017","journal-title":"Journal of integrative medicine"},{"issue":"3","key":"10.1016\/j.micpath.2024.107003_bib77","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1007\/s11033-022-08158-7","article-title":"Polymorphisms in drug metabolism genes as a risk factor for first-line anti-tuberculosis drug-induced liver injury","volume":"50","author":"Meitei","year":"2023","journal-title":"Mol. Biol. Rep."},{"issue":"3","key":"10.1016\/j.micpath.2024.107003_bib78","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.tube.2014.02.003","article-title":"Association of NAT2, GST and CYP2E1 polymorphisms and anti-tuberculosis drug-induced hepatotoxicity","volume":"94","author":"Singla","year":"2014","journal-title":"Tuberculosis"},{"issue":"5","key":"10.1016\/j.micpath.2024.107003_bib79","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1111\/j.1365-2710.2012.01334.x","article-title":"CYP2E1, GSTM1 and GSTT1 genetic polymorphisms and susceptibility to antituberculosis drug-induced hepatotoxicity: a nested case-control study","volume":"37","author":"Tang","year":"2012","journal-title":"J. Clin. Pharm. Therapeut."},{"issue":"8","key":"10.1016\/j.micpath.2024.107003_bib80","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1002\/pds.3988","article-title":"Prevalence, risk factors, management, and treatment outcomes of first-line antituberculous drug-induced liver injury: a prospective cohort study","volume":"25","author":"Sun","year":"2016","journal-title":"Pharmacoepidemiol. Drug Saf."}],"container-title":["Microbial Pathogenesis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0882401024004704?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0882401024004704?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,24]],"date-time":"2024-10-24T13:10:38Z","timestamp":1729775438000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0882401024004704"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":79,"alternative-id":["S0882401024004704"],"URL":"https:\/\/doi.org\/10.1016\/j.micpath.2024.107003","relation":{},"ISSN":["0882-4010"],"issn-type":[{"value":"0882-4010","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Alcohol consumption as a risk factor for anti-tuberculosis drug induced liver injury: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Microbial Pathogenesis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.micpath.2024.107003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"107003"}}